Efficacy and Safety of Telitacicept for the Treatment of IgA Nephropathy Patients: A Retrospective Real-World Study

Efficacy and Safety of Telitacicept for the Treatment of IgA Nephropathy Patients: A Retrospective Real-World Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Efficacy and Safety of Telitacicept for the Treatment of IgA Nephropathy Patients: A Retrospective Real-World Study Xiang Lyu, Xun Tang, Yujing Zhou, Jun Zhang, Tingting Guo, Qianyin Huang, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8722163/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background This real-world study aimed to evaluate the efficacy and safety of telitacicept in the treatment of immunoglobulin A nephropathy (IgAN). Methods Fifty-seven patients with biopsy-confirmed IgAN who received telitacicept between July 2022 and August 2025 were enrolled. Changes in urinary protein excretion, renal function, urinary red blood cell count, and adverse events were assessed from 2 to 12 months post-treatment. Subgroup analyses were performed based on baseline proteinuria levels and estimated glomerular filtration rate (eGFR). Changes in proteinuria and renal function following telitacicept discontinuation were also observed. Results Significant reductions in proteinuria were observed as early as 2 months into therapy, with median decreases in u rine albumin-to-creatinine ratio (UACR), urine protein-to-creatinine ratio (UPCR), and 24-hour urine protein excretion (24hUP) of 42.3%, 48.7%, and 56.2%, respectively (P < 0.0001). These reductions continued to progress, reaching approximately 80% at 12 months. eGFR and serum creatinine levels remained stable throughout the observation period. Concurrently, urinary red blood cell counts (U-RBC) decreased significantly, exhibiting a 92.7% reduction at month 12. Subgroup analysis indicated that patients across various baseline proteinuria levels and eGFR ranges benefited from the treatment, with those having baseline 24hUP between 1 and 3.5 g/day or an eGFR ≥ 45 mL/min/1.73 m² experiencing more pronounced efficacy. The overall adverse event (AE) rate was 7.0%, with no serious adverse events (SAEs) observed. The therapeutic effect persisted for up to 14 months after discontinuation of telitacicept. Conclusions Telitacicept provides a rapid and sustained reduction in proteinuria, stabilizes renal function, and demonstrates a favorable safety profile in patients with IgAN. IgA nephropathy Telitacicept Advanced chronic kidney disease BLyS/APRIL inhibitor Proteinuria Full Text Additional Declarations No competing interests reported. Supplementary Files LyuetalBMCNephrologyTelitaciceptinIgANSupplementaryMaterials.zip Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8722163","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":591724058,"identity":"a32d8cb7-1cd1-42b3-8925-7b89a252e61f","order_by":0,"name":"Xiang Lyu","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Xiang","middleName":"","lastName":"Lyu","suffix":""},{"id":591724059,"identity":"de0db1a3-34fc-4654-abb6-50bb394eddda","order_by":1,"name":"Xun Tang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA0UlEQVRIiWNgGAWjYBACNvaG9B8f/9nwsLE3HyBOCx/PgQeSM9jSZPh4jiUQp0VOIvGBNAfbYRs5iRwDIh3GczjBmIGHmYeN58zHG28Y7OR0GwhpYW9LSC6QYAP6pXez5RyGZGOzAwRtOZNweIYBD9CWs9ukeRgOJG4jqEUi/2MzT4IED5tEzjNitSQkM/McMABpYSNSC8+BNMaZDQlAhx0ztpxjQIRf5Nsb0hg+Nvy3l29vfnjjTYWdHEEtKECCh8ioQdZCqo5RMApGwSgYEQAA1RA8p/NuDnkAAAAASUVORK5CYII=","orcid":"","institution":"Southern Medical University","correspondingAuthor":true,"prefix":"","firstName":"Xun","middleName":"","lastName":"Tang","suffix":""},{"id":591724060,"identity":"04755ab7-baca-4a45-a7e6-6fe67cceef42","order_by":2,"name":"Yujing Zhou","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yujing","middleName":"","lastName":"Zhou","suffix":""},{"id":591724061,"identity":"50ecdfff-28be-4ce1-b56c-335bd12bbc1e","order_by":3,"name":"Jun Zhang","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Jun","middleName":"","lastName":"Zhang","suffix":""},{"id":591724062,"identity":"641f58eb-7658-4095-81e2-262127588c96","order_by":4,"name":"Tingting Guo","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Tingting","middleName":"","lastName":"Guo","suffix":""},{"id":591724063,"identity":"3dc223b6-6999-48c8-8d04-6f4b92698fcb","order_by":5,"name":"Qianyin Huang","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Qianyin","middleName":"","lastName":"Huang","suffix":""},{"id":591724064,"identity":"e147aed9-d6fe-48e4-9e75-47b0749f59f3","order_by":6,"name":"Qijing Zhang","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Qijing","middleName":"","lastName":"Zhang","suffix":""},{"id":591724065,"identity":"9c2a9069-cfa1-4a30-abc0-51efe4011be7","order_by":7,"name":"Junli Jin","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Junli","middleName":"","lastName":"Jin","suffix":""},{"id":591724066,"identity":"b1f4951b-f953-42e5-a04a-94cf4c4a6ba7","order_by":8,"name":"Qi Ye","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Qi","middleName":"","lastName":"Ye","suffix":""},{"id":591724067,"identity":"cbb24b58-23e3-4e7f-911b-35c68ae0d793","order_by":9,"name":"Zirui Chen","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Zirui","middleName":"","lastName":"Chen","suffix":""},{"id":591724068,"identity":"6ca5ff2d-7bb5-4ccf-a562-6059dab7e51b","order_by":10,"name":"Yanling Xie","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yanling","middleName":"","lastName":"Xie","suffix":""},{"id":591724069,"identity":"a6edbc9a-5b74-43dd-b3a7-11bd6ad32dc8","order_by":11,"name":"Shuqing Yuan","email":"","orcid":"","institution":"Southern Medical University","correspondingAuthor":false,"prefix":"","firstName":"Shuqing","middleName":"","lastName":"Yuan","suffix":""}],"badges":[],"createdAt":"2026-01-28 14:39:55","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8722163/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8722163/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":103394409,"identity":"2022e839-251a-4723-bd21-ec42b5022df5","added_by":"auto","created_at":"2026-02-25 08:27:39","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":676064,"visible":true,"origin":"","legend":"","description":"","filename":"LyuetalBMCNephrologyManuscriptREVISED.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8722163/v1_covered_2a4a00b4-a181-47f2-9429-67e4f26e0e60.pdf"},{"id":102768543,"identity":"e5789f25-c11d-4d01-9c32-416238e4464b","added_by":"auto","created_at":"2026-02-16 12:00:04","extension":"zip","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":193691,"visible":true,"origin":"","legend":"","description":"","filename":"LyuetalBMCNephrologyTelitaciceptinIgANSupplementaryMaterials.zip","url":"https://assets-eu.researchsquare.com/files/rs-8722163/v1/53689b290909093fdc95e92f.zip"}],"financialInterests":"No competing interests reported.","formattedTitle":"Efficacy and Safety of Telitacicept for the Treatment of IgA Nephropathy Patients: A Retrospective Real-World Study","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"IgA nephropathy, Telitacicept, Advanced chronic kidney disease, BLyS/APRIL inhibitor, Proteinuria","lastPublishedDoi":"10.21203/rs.3.rs-8722163/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8722163/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eThis real-world study aimed to evaluate the efficacy and safety of telitacicept in the treatment of immunoglobulin A nephropathy (IgAN).\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eFifty-seven patients with biopsy-confirmed IgAN who received telitacicept between July 2022 and August 2025 were enrolled. Changes in urinary protein excretion, renal function, urinary red blood cell count, and adverse events were assessed from 2 to 12 months post-treatment. Subgroup analyses were performed based on baseline proteinuria levels and estimated glomerular filtration rate (eGFR). Changes in proteinuria and renal function following telitacicept discontinuation were also observed.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eSignificant reductions in proteinuria were observed as early as 2 months into therapy, with median decreases in \u003cb\u003eu\u003c/b\u003erine albumin-to-creatinine ratio (UACR), urine protein-to-creatinine ratio (UPCR), and 24-hour urine protein excretion (24hUP) of 42.3%, 48.7%, and 56.2%, respectively (P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). These reductions continued to progress, reaching approximately 80% at 12 months. eGFR and serum creatinine levels remained stable throughout the observation period. Concurrently, urinary red blood cell counts (U-RBC) decreased significantly, exhibiting a 92.7% reduction at month 12. Subgroup analysis indicated that patients across various baseline proteinuria levels and eGFR ranges benefited from the treatment, with those having baseline 24hUP between 1 and 3.5 g/day or an eGFR\u0026thinsp;\u0026ge;\u0026thinsp;45 mL/min/1.73 m\u0026sup2; experiencing more pronounced efficacy. The overall adverse event (AE) rate was 7.0%, with no serious adverse events (SAEs) observed. The therapeutic effect persisted for up to 14 months after discontinuation of telitacicept.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eTelitacicept provides a rapid and sustained reduction in proteinuria, stabilizes renal function, and demonstrates a favorable safety profile in patients with IgAN.\u003c/p\u003e","manuscriptTitle":"Efficacy and Safety of Telitacicept for the Treatment of IgA Nephropathy Patients: A Retrospective Real-World Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-16 11:59:59","doi":"10.21203/rs.3.rs-8722163/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8d187da2-2e48-45a1-92fb-d6e550393309","owner":[],"postedDate":"February 16th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-02-25T08:26:42+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-16 11:59:59","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8722163","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8722163","identity":"rs-8722163","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}